A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
Latest Information Update: 26 Feb 2025
At a glance
- Drugs MB 310 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; First in man
- Acronyms COMPOSER-1
- Sponsors Microbiotica
Most Recent Events
- 13 Nov 2024 According to Microbiotica Media release, Walter Reinisch is the principal investigator in the study.
- 13 Nov 2024 According to Microbiotica Media release, first patient has been dosed in this study and Initial data readouts are expected by the end of 2025.
- 13 Nov 2024 Status changed from not yet recruiting to recruiting as per Microbiotica media release.